ZAP Surgical Announces US$81 Million Financing Round

外科系统公司ZAP获8100万美元融资,将用于推进手术机器人商业化

2020-01-09 08:40:16 CISION

本文共1381个字,阅读需4分钟

 ZAP Surgical Systems, Inc., a medical technology company developing a next-generation radiosurgical robot for non-invasive tumor ablation, today announced the completion of an equity financing round that raised an aggregate total of US$81 million. The round was led by Primavera Capital Group, with participation from GT Healthcare Capital Partners, Chow Tai Fook Enterprises, ShangBay Capital, and Hogy Medical, who joined existing investors Foxconn Technology Group and Varian Medical Systems. The Company has now raised more than US$160 million in financing capital to date. Funds from the latest financing round will be used to accelerate the commercialization of the Company's FDA cleared ZAP-X® surgical robot for the treatment of cancer and other brain disorders. "Although over the past 3 decades stereotactic radiosurgery has become a well-established non-invasive tool for treating a broad array of human pathologies, globally more than 2 million people who suffer from brain, head & neck cancer annually go untreated," said John R. Adler, MD, Stanford Professor of Neurosurgery and founder & CEO of ZAP Surgical Systems. "ZAP Surgical welcomes this group of world-class investors in our now common quest to transform the lives, and very often cure, millions of patients each year by means of the ZAP-X surgical robot." "We are very excited to be a part of this highly promising, innovative, mission-driven medical device company at an early stage in its commercial development," said Dr. Fred Hu, Chairman and Founder of Primavera Capital Group. "Dr. Adler is a true visionary in this field, and his team's latest invention will provide cutting-edge technology to millions of patients around the world. It fits Primavera's mission of supporting entrepreneurs who combine both commercial success and social impact globally." The ZAP-X platform is an integrated robotic software and hardware solution currently FDA-cleared to provide image-guided stereotactic radiosurgery for tumors, lesions and conditions in the brain, head and neck. ZAP-X incorporates a unique self-shielded design that typically eliminates the need for costly radiation bunkers. Combining this first-in-kind vault-free design with cobalt-free radiation delivery, the ZAP-X platform enables significant improvements to the delivery of cost-effective care with the goal of bringing world-class non-invasive radiosurgery to more providers, and subsequently, more patients. About ZAP Surgical Systems, Inc.ZAP Surgical Systems, Inc. designs and manufactures the ZAP-X® radiosurgery platform. ZAP was founded in 2014 by John R. Adler, MD, Stanford Professor of Neurosurgery and founder & CEO of ZAP Surgical Systems. Dr. Adler is also the inventor of the CyberKnife® and founder of Accuray, Inc. FDA-cleared in September 2017, ZAP-X incorporates a unique self-shielded design that typically eliminates the need for traditional radiation vaults, and thus enables simple point-of-care delivery in locations previously unfeasible or cost-prohibitive, including physician offices, ambulatory surgery centers, and satellite facilities. Learn more at www.ZAPsurgical.com. Contact:Gabriel MorrisInvestor RelationsZAP Surgical Systems, Inc.Email: gabriel@zapsurgical.com Mark ArnoldSenior Vice President, MarketingZAP Surgical Systems, Inc.Email: marka@zapsurgical.com SOURCE ZAP Surgical Systems Related Links https://zapsurgical.com/
ZAP 外科系统公司是一家开发下一代无创肿瘤消融放射外科机器人的医疗技术公司,该公司今天宣布完成一轮股权融资,融资总额为8100万美元。本轮融资由 Primavera Capital Group 牵头,由 GT Healthcare Capital Partners 、 Chow Tai Fook Enterprises 、上海湾资本和 Hogy Medical 共同参与,他们加入了现有投资者富士康科技集团( Foxconn Technology Group )和 Varian Medical Systems 。到目前为止,该公司已经筹集了超过1.6亿美元的融资资本。来自最近一轮融资的资金将用于加快公司 FDA 批准的用于治疗癌症和其他脑部疾病的 ZAP-X ®手术机器人的商业化。 约翰· R ·阿德勒博士说:“尽管过去30年来,立体定向放射外科已经成为一种公认的治疗多种人类病理的非侵入性工具,但全球每年有200多万患有脑、头颈癌的人未经治疗。”斯坦福神经外科教授, ZAP 外科系统的创始人兼首席执行官。“ ZAP 外科欢迎这个世界级的投资者,在我们现在共同的追求,以改变生活,往往治愈,每年数百万患者,通过 ZAP-X 手术机器人。” Primavera Capital Group 董事长兼创始人 Fred Hu 博士说:“我们非常高兴能在商业发展的早期阶段成为这家充满希望、创新、使命驱动的医疗器械公司的一部分。”阿德勒博士是这一领域的真正有远见的人,他的团队的最新发明将为世界各地的数百万病人提供尖端技术。这符合 Primavera 的使命,即支持将商业成功和社会影响结合在一起的企业家。” ZAP-X 平台是一种集成的机器人软件和硬件解决方案,目前已获得 FDA 批准,为肿瘤、脑、头颈病变和状况提供影像引导的立体定向放射手术。ZAP-X 采用了独特的自我保护设计,典型地消除了昂贵的辐射掩体的需要。ZAP-X 平台将这种无保险库的首次设计与无钴辐射传输相结合,能够显著改善成本效益高的医疗服务的交付,目的是为更多的提供者提供世界级的无创放射外科手术,并随后为更多的病人提供服务。 关于 ZAP 手术系统公司, ZAP 手术系统公司设计和制造 ZAP-X ®放射手术平台。ZAP 成立于2014年,由斯坦福神经外科教授、 ZAP 外科系统创始人兼首席执行官 John R . Adler 博士创立。 Adler 博士也是 CyberKnife ®的发明者, Accury , Inc .的创始人,于2017年9月获得 FDA 批准, ZAP-X 采用了独特的自我屏蔽设计,典型地消除了对传统辐射保险库的需求。因此,能够在先前不可行或成本高昂的地点,包括医生办公室、门诊手术中心和卫星设施,提供简单的护理点。详情请访问 www.ZAP.com 。 联系方式: Gabriel MorrisInvestor Relations ZAP 手术系统公司电子邮件: gabriel @ zapsurgical.com Mark Arnoldd MarketingZAP 外科系统公司高级副总裁,电子邮件: marka @ zapsurgical.com SOURCE ZAP 手术系统 相关链接 https://zapsurgical 。com /

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文